CVRx Q2 2023 Earnings Report $11.56 +0.26 (+2.30%) As of 03/11/2025 04:00 PM Eastern Earnings HistoryForecast CVRx EPS ResultsActual EPS-$0.56Consensus EPS -$0.57Beat/MissBeat by +$0.01One Year Ago EPSN/ACVRx Revenue ResultsActual Revenue$9.50 millionExpected Revenue$8.56 millionBeat/MissBeat by +$940.00 thousandYoY Revenue GrowthN/ACVRx Announcement DetailsQuarterQ2 2023Date7/25/2023TimeN/AConference Call ResourcesPress ReleaseCVRX Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Remove Ads CVRx Earnings HeadlinesCVRx (NASDAQ:CVRX) and Vivos Therapeutics (NASDAQ:VVOS) Critical AnalysisMarch 6, 2025 | americanbankingnews.comCVRx's SWOT analysis: barostim maker's stock faces reimbursement hurdlesFebruary 17, 2025 | msn.comElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest breakthrough in artificial intelligence… but in human technology. It’s so valuable that some are referring to it as the “new gold”.March 12, 2025 | True Market Insiders (Ad)CVRx reports on ‘significant reductions in healthcare utilization’ with BarostimFebruary 12, 2025 | markets.businessinsider.comCVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with BarostimFebruary 12, 2025 | globenewswire.comCVRx Full Year 2024 Earnings: EPS Misses ExpectationsFebruary 6, 2025 | finance.yahoo.comSee More CVRx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CVRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CVRx and other key companies, straight to your email. Email Address About CVRxCVRx (NASDAQ:CVRX), a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.View CVRx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles These 3 Q1 Earnings Winners Will Go HigherAnalysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before Earnings Upcoming Earnings PDD (3/19/2025)Micron Technology (3/20/2025)Accenture (3/20/2025)FedEx (3/20/2025)NIKE (3/20/2025)Cintas (3/26/2025)Paychex (4/1/2025)Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
